Home » JOHNSON & JOHNSON 'NEUTRAL,' TARGET PRICE REDUCED
JOHNSON & JOHNSON 'NEUTRAL,' TARGET PRICE REDUCED
Analyst Glenn Novarro of Banc of America Securities maintains his "neutral"
rating on Johnson & Johnson. The target price has been reduced from $72
to $65.
Newratings
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May